Selecting a formulation partner is one of the more consequential decisions a pharmaceutical development team will make. Unlike choosing a supplier for raw materials or packaging, engaging a formulation company creates a deep dependency — on their scientific judgment, their regulatory track record, their equipment capabilities, and their willingness to communicate clearly when problems arise.
Too often, organizations finalize contracts without asking the right questions upfront. They focus on timelines and pricing but overlook areas like quality system maturity, technology fit, or how disagreements are handled mid-project. This leads to delays, cost overruns, and in some cases, failed batches or regulatory setbacks that could have been anticipated.
The questions below are designed to surface the information that actually determines whether a partnership will hold up under operational pressure. They apply whether you are in early-stage development, scaling to clinical supply, or transitioning from a previous formulation partner.
Understanding What You Are Actually Evaluating
Before the contract conversation begins, it helps to understand what separates a capable drug product formulation company from one that may be technically adequate but poorly suited to your program. When you engage a drug product formulation company, you are not simply purchasing a service — you are entering a working relationship that affects your regulatory submissions, your clinical timelines, and ultimately, your product’s path to market. The evaluation should reflect that weight.
Many companies present well at the proposal stage. Equipment lists look current, team credentials are strong, and quality language is polished. What the proposal rarely shows is how the organization behaves when a formulation does not perform as expected, or how they manage competing priorities across client programs. That reality only becomes visible through structured, specific questions.
Why Generic Evaluation Frameworks Fall Short
Standard RFP checklists tend to ask about capacity, certifications, and turnaround times. These are not unimportant, but they do not tell you whether the team has experience with your specific dosage form, whether their quality systems are genuinely integrated into project work, or whether their scientists are empowered to raise concerns early rather than push projects forward to meet deadlines. A more targeted set of questions gets closer to that information.
The Ten Questions Worth Asking
1. What is your direct experience with this dosage form and route of administration?
General formulation capability does not always translate into specific expertise. A company experienced in oral solid dose may have limited depth in modified-release systems, inhalation products, or sterile injectables. Asking for concrete examples of completed projects — including any that encountered significant formulation challenges — gives you a clearer picture than a capabilities overview ever will.
2. How do you structure the project team, and who is the primary scientific contact?
Project management and scientific accountability are different functions, and how a company handles both matters. If your primary contact is a project manager who relays information between you and the formulation scientists, important technical nuances can get lost. Understanding who owns scientific decisions, and how accessible that person is to your team, affects how efficiently problems get resolved.
3. What does your quality management system look like in practice, not just on paper?
Most formulation companies can describe their quality systems in formal terms. The more useful question is how those systems function day to day. How are deviations documented and reviewed? How long does a batch record review typically take? What happens when an out-of-specification result occurs mid-study? As described by the FDA’s guidance on pharmaceutical quality systems, quality is not simply about compliance documentation — it reflects how an organization integrates scientific understanding with process controls. Asking for real examples reveals the difference.
4. How do you manage workload across concurrent client programs?
Capacity on paper and available capacity in practice are not the same thing. A contract organization running multiple programs simultaneously must allocate equipment time, laboratory resources, and technical staff across competing priorities. Understanding how they handle this — whether through dedicated resource allocation, clearly defined scheduling systems, or some other mechanism — tells you a great deal about whether your program will receive consistent attention or get deprioritized during busy periods.
5. What is your approach to intellectual property protection?
Formulation work involves sharing proprietary compound data, synthesis routes, and development strategies. Before any technical information changes hands, you need to understand how the company handles confidential information internally, what access controls exist, and how they approach IP ownership for formulation inventions that arise during the engagement. Contracts alone are not sufficient — the underlying practices matter.
6. How do you handle scope changes and unexpected technical challenges?
Formulation development is inherently iterative. Stability results do not always support the initial hypothesis. Scale-up can reveal processing variables that were not visible at the bench. When those situations arise, how a company communicates with clients — and how they structure change management into the contract — determines whether the project stays on track or creates friction. Ask for a specific example of how they navigated a formulation setback with a previous client.
7. What analytical capabilities do you have in-house, and where are the gaps?
A drug product formulation company that relies heavily on third-party analytical labs for characterization work introduces coordination risk, longer turnaround times, and potential gaps in data continuity. Understanding which analytical methods are performed in-house, which are sent out, and how they manage data integrity across those boundaries affects both program timelines and the reliability of your development dataset.
8. How do you approach technology transfer if we need to move to a different facility?
Not all programs stay with the same contract organization from development through commercial manufacture. Whether due to scale requirements, geographic considerations, or regulatory strategy, technology transfer is a real possibility. A company that has structured and well-documented transfer processes — including batch records, method documentation, and process parameters — makes that transition manageable. One that has not thought carefully about this creates significant downstream risk.
9. What is your experience with regulatory submissions related to this dosage form?
Formulation development and regulatory strategy are closely connected. The choices made during development affect what can be claimed in submissions, how changes are managed post-approval, and what flexibility exists in manufacturing. A drug product formulation company with direct experience supporting IND, NDA, or ANDA submissions for your type of product brings a level of practical regulatory awareness that goes beyond scientific competence. Ask specifically about their role in recent submissions and any feedback received from regulatory agencies.
10. What does the governance structure for this engagement look like?
Governance refers to how decisions are made, escalated, and documented throughout the project. Who signs off on major technical decisions? How are disagreements between scientific teams resolved? What triggers a formal project review? Organizations that have answered these questions in advance — and that can describe their governance approach clearly — tend to run more predictable programs. Those that handle governance informally are more likely to experience communication breakdowns under pressure.
Reading the Answers Carefully
How a company answers these questions is often as informative as what they say. A team that responds to technical questions with marketing language, deflects specifics with vague reassurances, or cannot point to concrete examples from past work is showing you something important. Capable organizations have institutional memory. They can describe real projects, real problems, and how those problems were resolved.
Be equally attentive to whether answers reflect genuine organizational capability or individual expertise. If the strength of the response depends entirely on one senior scientist who may or may not be assigned to your program, that is a risk worth acknowledging. Systems and processes outlast individual contributors. That is what you are ultimately evaluating.
Using These Questions to Structure the Negotiation
These questions are not just for due diligence — they can directly inform contract language. If a company describes a particular approach to change management, intellectual property, or technology transfer, that description should have a corresponding provision in the agreement. Gaps between stated practices and contract language are worth clarifying before you sign, not after a problem has already emerged.
Closing Thoughts
Choosing a drug product formulation company is a decision with long-term consequences for your development program. The contract represents a commitment that extends across months or years of technical work, regulatory interaction, and resource allocation. Getting that choice right depends on having a clear picture of the organization before the agreement is finalized — not just their capabilities, but their practices, their communication patterns, and their track record under real working conditions.
The ten questions outlined here are not exhaustive. Specific compound properties, regulatory pathways, and program complexities will generate additional considerations. But these questions address the areas most likely to determine whether the engagement runs smoothly or produces the kind of friction that costs time, money, and sometimes program viability.
Taking the time to ask them carefully, and to listen to the answers with the same care, is one of the more practical investments a development team can make before a contract is signed. It does not guarantee a perfect outcome — no question set can — but it reduces the likelihood of unpleasant surprises once the work is underway.
